Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Clinical and genomic diagnosis of smoldering myeloma & identifying patients at risk of progression

Niccolò Bolli • 25 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on the discordance between clinically and genomically-defined smoldering myeloma, explaining how this can be used to find patients at high risk of progression to multiple myeloma and initiate treatment early. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Niccolò Bolli

2:26
The role of the bone marrow immune microenvironment on response to treatment in multiple myeloma
Niccolò Bolli • 25 Aug 2022
2:52
Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
Niccolò Bolli • 25 Sep 2022
2:43
Session highlights: clonal hematopoiesis in multiple myeloma
Niccolò Bolli • 25 Aug 2022
4:02
The association between CHIP and MGUS
Niccolò Bolli • 12 Dec 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals